A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis

Dose-Response and Efficacy of Ferric Citrate to Treat Hyperphosphatemia in Hemodialysis Patients: A Short-term Randomized Trial

(2013) Jamie P. Dwyer et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Ferric Citrate Hydrate, a New Phosphate Binder, Prevents the Complications of Secondary Hyperparathyroidism and Vascular Calcification

(2013) Akio Iida et al.   AMERICAN JOURNAL OF NEPHROLOGY

Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder

(2013) Masafumi Fukagawa et al.   THERAPEUTIC APHERESIS AND DIALYSIS

Effect of Oral JTT-751 (Ferric Citrate) on Hyperphosphatemia in Hemodialysis Patients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

(2012) Keitaro Yokoyama et al.   AMERICAN JOURNAL OF NEPHROLOGY

Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s)

(2012) Tilman B. Drüeke et al.   KIDNEY INTERNATIONAL

The Safety and Tolerability of Ferric Citrate as a Phosphate Binder in Dialysis Patients

(2012) Marvin Sinsakul et al.   NEPHRON CLINICAL PRACTICE

The Phosphate Binder Equivalent Dose

(2011) John T. Daugirdas et al.   SEMINARS IN DIALYSIS

Oral Phosphate Binders in Patients with Kidney Failure

(2010) Marcello Tonelli et al.   NEW ENGLAND JOURNAL OF MEDICINE

Foreword

(2009) Kai-Uwe Eckardt et al.   KIDNEY INTERNATIONAL